BestBitcoinMining.com

Press Release: Basilea reports significant revenue growth from marketed products and pipeline …

Press Release: Basilea reports significant revenue growth from marketed products and pipeline progress for full-year 2019

Revenue contributions from Cresemba(R) and Zevtera(R) increased 39% to CHF 114 million — Operating result improved by 29% — Start of urothelial cancer study for derazantinib with immunotherapy combination and further expansion planned into gastric cancer — Positive topline results reported from ceftobiprole phase 3 skin infection (ABSSSI) study — Year-end cash and investments of CHF 161 million and reduction in net operating cash consumption — In 2020, revenue contributions from Cresemba and Zevtera, excluding deferred revenue, expected to grow 12% to 27% year-on-year Basel, Switzerland, February 18, 2020 — Basilea Pharmaceutica Ltd.







BestBitcoinMining.com